Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
The new patents cover critical advancements in cochlear implant technology
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Under the deal, Quiver will receive an undisclosed advance payment and research support
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
Subscribe To Our Newsletter & Stay Updated
